The reality of using primaquine.

Area of Science:

• Tropical Medicine
• Pharmacology
• Hematology

Background:

• Primaquine is the sole radical cure for Plasmodium vivax.
• Glucose-6-phosphate dehydrogenase (G6PD) deficiency increases hemolysis risk with primaquine.
• This risk is preventable through G6PD testing and patient education.

Observation:

• A G6PD deficient patient experienced intravascular hemolysis after taking primaquine and chloroquine.
• The patient misunderstood instructions due to language barriers and lack of G6PD testing.
• Prompt treatment led to the patient's recovery.

Findings:

• Undiagnosed G6PD deficiency combined with primaquine can cause severe, potentially fatal, hemolysis.
• Misunderstanding medication instructions exacerbates the risk of adverse drug reactions.
• Early diagnosis and appropriate patient counseling are vital for safe primaquine use.

Implications:

• G6PD testing should be standard practice before primaquine administration in P. vivax endemic areas.
• Clear, understandable patient information is essential to prevent adverse events.
• Minimizing primaquine risks is critical for effective P. vivax treatment and transmission control.